- Home
- ADD vs RVPH Comparison
ADD vs RVPH Comparison
Compare ADD & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADD
- RVPH
- Stock Information
- Founded
- ADD 2002
- RVPH 2006
- Country
- ADD United States
- RVPH United States
- Employees
- ADD N/A
- RVPH N/A
- Industry
- ADD Engineering & Construction
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- ADD Consumer Discretionary
- RVPH Health Care
- Exchange
- ADD Nasdaq
- RVPH Nasdaq
- Market Cap
- ADD 33.8M
- RVPH 37.1M
- IPO Year
- ADD N/A
- RVPH N/A
- Fundamental
- Price
- ADD $1.32
- RVPH $1.15
- Analyst Decision
- ADD
- RVPH Strong Buy
- Analyst Count
- ADD 0
- RVPH 4
- Target Price
- ADD N/A
- RVPH $14.33
- AVG Volume (30 Days)
- ADD 487.0K
- RVPH 862.2K
- Earning Date
- ADD 06-01-2024
- RVPH 08-14-2024
- Dividend Yield
- ADD N/A
- RVPH N/A
- EPS Growth
- ADD N/A
- RVPH N/A
- EPS
- ADD N/A
- RVPH N/A
- Revenue
- ADD $1,060,442.00
- RVPH N/A
- Revenue This Year
- ADD N/A
- RVPH N/A
- Revenue Next Year
- ADD N/A
- RVPH N/A
- P/E Ratio
- ADD N/A
- RVPH N/A
- Revenue Growth
- ADD N/A
- RVPH N/A
- 52 Week Low
- ADD $0.17
- RVPH $0.60
- 52 Week High
- ADD $1.86
- RVPH $6.80
- Technical
- Relative Strength Index (RSI)
- ADD 77.70
- RVPH 50.86
- Support Level
- ADD $0.57
- RVPH $0.95
- Resistance Level
- ADD $1.49
- RVPH $1.57
- Average True Range (ATR)
- ADD 0.21
- RVPH 0.14
- MACD
- ADD 0.07
- RVPH 0.01
- Stochastic Oscillator
- ADD 96.25
- RVPH 30.16
About ADD Color Star Technology Co. Ltd.
Color Star Technology Co Ltd is an entertainment technology and education company providing online and offline music education. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.